Company intelligence / Profile preview

Novochizol SA

Monthey, Valais, Switzerlandnovochizol.ch ↗

Ownership: Private
Development stage: Preclinical

Overview

Novochizol’s technology has demonstrated strong preclinical safety and efficacy in animal models, showing local, sustained release with minimal systemic effects. No human clinical trials have been reported as of June 2025. The company is pursuing regulatory qualification for pharmaceutical use.

Therapeutic areas: OncologyPulmonologyDermatologyRheumatology
Modalities: Small moleculesPeptidesNucleic acidsProteins
Industry: Biotech

Drug pipeline

1 asset

botulinum toxin-Novochizol

Pre-clinical

Indications: Atrial fibrillation

Partnerships

Boehringer Ingelheim – winner of the opnMe novel drug delivery solutions contest, indicating collaboration or recognition by a major pharma partner.

Beyond the preview

Go deeper on Novochizol SA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novochizol SA.

Explore the full profile